Clinical trials in Bari – page 16

393 clinical trials in Bari, Italy across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Bari at a glance

393

clinical trials

Research sites3

Quick filters

393 trials in Bari

Open in trial search

Type 2 diabetes mellitus

Not yet recruiting

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Comparison of weekly insulin icodec versus daily basal insulin in adults with type 2 diabetes who have not used insulin before

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:INSULIN DEGLUDEC
Sponsor:Novo Nordisk A/S

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study of amivantamab and pemetrexed for patients with non-small cell lung cancer who have EGFR exon20 insertion mutations and cannot receive platinum therapy

Registered drugNo placebo

Study of amivantamab and pemetrexed for patients with non-small cell lung cancer who have EGFR exon20 insertion mutations and cannot receive platinum therapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amivantamab
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo

Study of gilteritinib with fludarabine, cytarabine and idarubicin combination therapy in newly diagnosed FLT3-positive acute myeloid leukemia patients

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Gilteritinib
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Torl Biotherapeutics LLC

Contact Research Centre

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study of Cabozantinib for Patients with Non-Small Cell Lung Cancer and MET Deregulation

Registered drugNo placebo

Study of Cabozantinib for Patients with Non-Small Cell Lung Cancer and MET Deregulation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Acute respiratory distress syndrome

Not yet recruiting

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug

Study on Pirfenidone for Preventing Lung Fibrosis in Patients with Acute Respiratory Distress Syndrome (ARDS)

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Pirfenidone
Sponsor:Ospedale San Raffaele S.r.l.

Contact Research Centre

Non-small cell lung cancer stage IIIA+1

Not yet recruiting

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Universita' Degli Studi Di Torino

Contact Research Centre

Non-small cell lung cancer

Not yet recruiting

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo

Study on the Best Treatment Sequence for Advanced Non-Small Cell Lung Cancer with EGFR Mutations Using Dacomitinib and Osimertinib

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dacomitinib
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Non-small cell lung cancer stage III

Not yet recruiting

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo

Study on Durvalumab and Chemotherapy for Patients with Relapsed Stage III Non-Small Cell Lung Cancer After Chemoradiotherapy and Durvalumab Treatment

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:Fondazione Ricerca Traslazionale

Contact Research Centre

Prostate cancer metastatic+1

Not yet recruiting

Study on Using Copper (64Cu) Chloride PET/CT Imaging for Prostate Cancer Patients with Biochemical Relapse After Surgery to Guide Radiation Therapy

InvestigationalNo placebo

Study on Using Copper (64Cu) Chloride PET/CT Imaging for Prostate Cancer Patients with Biochemical Relapse After Surgery to Guide Radiation Therapy

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Copper (64Cu) Chloride
Sponsor:A.C.O.M. Advanced Center Oncology Macerata S.r.l.

Contact Research Centre

Genitourinary tract neoplasm

Not yet recruiting

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo

Study on Niraparib for Patients with Advanced Urothelial Cancer After Initial Platinum Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate
Sponsor:Universita' Degli Studi Di Torino

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Bari

What the registry says about research in the country

01 Oncology Research

Studies focusing on innovative treatments for various cancers, including metastatic colorectal cancer, non-small cell lung cancer, and malignant pleural mesothelioma. Research evaluates new therapeutic approaches and drug combinations.

Colorectal Cancer Treatment Studies
Lung Cancer Therapies
Mesothelioma Management

Advanced clinical trials testing targeted therapies and immunotherapy approaches.

02 Infectious Disease Prevention

Investigations into vaccines and preventive treatments for various infectious conditions, particularly respiratory syncytial virus (RSV) and influenza. Studies include both pediatric and adult populations.

Vaccine Development
RSV Prevention
Influenza Protection

Focus on immunogenicity and safety in different age groups.

03 Hematologic Disorders

Research examining treatments for blood-related conditions, including chronic myeloid leukemia and acute myeloid leukemia. Studies evaluate novel therapeutic approaches and drug combinations.

Leukemia Treatments
Targeted Therapies
Clinical Outcomes

Emphasis on personalized treatment approaches and molecular targeting.

Back to Italy All countries